Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
351 search results for:

Vilanterol 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 01-12-2024 | Umeclidinium | Erratum

    Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

    HCRU and costs following FF/UMEC/VI initiation.

    Author:
    Afisi S. Ismaila, Kieran J. Rothnie, Robert P. Wood, Victoria L. Banks, Lucinda J. Camidge, Alexandrosz Czira, Chris Compton, Raj Sharma, Shannon N. Millard, Olivia Massey, David M. G. Halpin
    Published in:
    Respiratory Research > Issue: 1 / 2024
  2. Open Access 01-12-2023 | Umeclidinium | OriginalPaper

    Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

    Escalation to triple therapy with an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting β 2 -agonist (LABA) is recommended for patients with chronic obstructive pulmonary disease (COPD) who continue to …

    Author:
    Afisi S. Ismaila, Kieran J. Rothnie, Robert P. Wood, Victoria L. Banks, Lucinda J. Camidge, Alexandrosz Czira, Chris Compton, Raj Sharma, Shannon N. Millard, Olivia Massey, David M. G. Halpin
    Published in:
    Respiratory Research > Issue: 1 / 2023
  3. 01-07-2021 | Umeclidinium | OriginalPaper

    Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN)

    Despite adherence to inhaled corticosteroids/long-acting β 2 -agonist (ICS/LABA) maintenance therapy, approximately 30–50% of patients with asthma are still not well controlled [ 1 – 4 ]. Guidelines from the Global Initiative for Asthma [ 5 ] …

    Author:
    Shuying Yang, Laurie A. Lee, Neal Sule, Andrew Fowler, Guy Peachey
    Published in:
    Clinical Pharmacokinetics > Issue: 7 / 2021
  4. 01-11-2018 | News

    Vilanterol/fluticasone furoate
    Tachycardia: case report
    Published in:
    Reactions Weekly > Issue: 1 / 2018
  5. 01-11-2016 | ReviewPaper

    Umeclidinium Plus Vilanterol Versus Placebo, Umeclidinium, or Vilanterol Monotherapies for Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials

    Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide and results in an economic and social burden that is both substantial and increasing [ 1 – 3 ]. Current treatment guidelines for COPD recommend …

    Author:
    Li Wang, Chun-juan Zhai, Yao Liu, Yi Liu, Shu-juan Jiang
    Published in:
    Clinical Drug Investigation > Issue: 11 / 2016
  6. 01-04-2017 | News

    Vilanterol/fluticasone furoate
    Palpitations: case report
    Published in:
    Reactions Weekly > Issue: 1 / 2017
  7. Open Access 04-02-2024 | Chronic Obstructive Lung Disease | OriginalPaper

    Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)

    Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition estimated to affect 4.6–6.6% of American adults [ 1 ], and is a leading cause of death worldwide [ 2 ]. The economic and social burden of COPD is considerable, with …

    Author:
    Meredith McCormack, Rosirene Paczkowski, Noelle N. Gronroos, Stephen G. Noorduyn, Lydia Lee, Phani Veeranki, Mary G. Johnson, Emmeline Igboekwe, Kristin Kahle-Wrobleski, Reynold Panettieri
    Published in:
    Advances in Therapy > Issue: 3 / 2024
  8. Open Access 01-12-2016 | OriginalPaper

    Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease

    Once-daily, combination pharmacological therapies have the potential to simplify treatment in chronic obstructive pulmonary disease (COPD) by reducing dosing frequency whilst increasing compliance [ 1 ]. Fluticasone furoate (FF; GW685698), a novel …

    Author:
    Sarah Siederer, Ann Allen, Shuying Yang
    Published in:
    European Journal of Drug Metabolism and Pharmacokinetics > Issue: 6 / 2016
  9. 01-12-2023 | Vilanterol | News

    Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamide/vilanterol/fluticasone-furoate interaction
    Adrenal insufficiency
    Published in:
    Reactions Weekly > Issue: 1 / 2023
  10. Open Access 01-12-2016 | OriginalPaper

    Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy

    Asthma is common in children and is a leading cause of childhood hospitalisation [ 1 ]. National and international guidelines advocate the use of inhaled long-acting beta-2 agonists (LABA) in combination with inhaled corticosteroids (ICS) as …

    Author:
    Amanda J. Oliver, Ronina A. Covar, Caroline H. Goldfrad, Ryan M. Klein, Søren E. Pedersen, Christine A. Sorkness, Susan A. Tomkins, César Villarán, Jonathan Grigg
    Published in:
    Respiratory Research > Issue: 1 / 2016
  11. 31-08-2023 | Bronchial Asthma | OriginalPaper

    Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma and/or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea

    Asthma is a heterogeneous disease usually characterised by chronic airway inflammation, with symptoms including wheezing, shortness of breath, chest tightness and coughing [ 1 – 3 ]. The presence of these symptoms varies over time and in intensity …

    Author:
    Eun-Yeong Cho, Jung-Eun Cho, Seung Hun Jang, Ki-Eun Hwang
    Published in:
    Drug Safety > Issue: 10 / 2023
  12. 01-12-2022 | Levofloxacin | News

    Levofloxacin/vilanterol/fluticasone-furoate
    Lack of efficacy: case report
    Published in:
    Reactions Weekly > Issue: 1 / 2022
  13. 01-07-2022 | Umeclidinium | News

    Fluticasone-furoate/umeclidinium/vilanterol
    Lack of efficacy: case report
    Published in:
    Reactions Weekly > Issue: 1 / 2022
  14. 01-07-2014 | OriginalPaper

    Population Pharmacokinetics of Inhaled Umeclidinium and Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

    Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation and reduced maximum expiratory flow that is not fully reversible [ 1 , 2 ]. World Health Organization projections show that COPD will become the third leading cause …

    Author:
    Navin Goyal, Misba Beerahee, Chris Kalberg, Alison Church, Sally Kilbride, Rashmi Mehta
    Published in:
    Clinical Pharmacokinetics > Issue: 7 / 2014
  15. Open Access 01-12-2021 | Umeclidinium | OriginalPaper

    Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study

    In patients with chronic obstructive pulmonary disease (COPD), exacerbations are associated with increased disease burden and higher healthcare costs [ 1 ]. As such, reducing the risk of exacerbations is an important goal of maintenance therapy in …

    Author:
    David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Malena Mahendran, Beth Hahn
    Published in:
    BMC Pulmonary Medicine > Issue: 1 / 2021
  16. Open Access 01-06-2021 | Umeclidinium | OriginalPaper

    Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease

    This article is published with digital features, including a summary slide and plain language summary, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.13953734 .

    Author:
    David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Sean D. MacKnight, Beth Hahn
    Published in:
    Pulmonary Therapy > Issue: 1 / 2021
  17. Open Access 01-12-2020 | Umeclidinium | OriginalPaper

    Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

    Chronic obstructive pulmonary disease (COPD) is a common respiratory disease characterized by chronic airflow limitation and persistent respiratory symptoms [ 1 ]. COPD is associated with a substantial clinical burden [ 1 ], was the third leading …

    Author:
    Nicola C. Day, Subramanya Kumar, Gerard Criner, Mark Dransfield, David M. G. Halpin, MeiLan K. Han, C. Elaine Jones, Morrys C. Kaisermann, Sally Kilbride, Peter Lange, David A. Lomas, Neil Martin, Fernando J. Martinez, Dave Singh, Robert Wise, David A. Lipson
    Published in:
    Respiratory Research > Issue: 1 / 2020
  18. Open Access 01-04-2023 | Umeclidinium | Letter

    Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis”
    Author:
    Jonathan Marshall, Akanksha Sharma, Patrick Darken, Mario Ouwens, Barinder Singh, Deniz Tansey-Dwyer
    Published in:
    Advances in Therapy > Issue: 5 / 2023
  19. Open Access 01-04-2023 | Umeclidinium | Letter

    A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
    Author:
    Afisi S. Ismaila, Katrin Haeussler, Mia Malmenäs, Raj Sharma, Chris Compton, Claus F. Vogelmeier, MeiLan K. Han, David M. G. Halpin
    Published in:
    Advances in Therapy > Issue: 5 / 2023
  20. 01-01-2021 | Aspergillus Fumigatus | News

    Prednisolone/vilanterol/fluticasone-furoate
    Bilateral septic arthritis of the knee joints caused by Methicillin-resistant Staphylococcus aureus: case report
    Published in:
    Reactions Weekly > Issue: 1 / 2021

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.